Furthermore, sJIA patients with higher levels of IL-18 are more likely to develop MAS, so that IL-18 levels could have a prognostic value and guide future therapeutic options, even in patients well controlled by other biologics, including anti-IL6 and anti-IL1 [248]. This evidence concerns the gene IL6 and macrophage activation syndrome.